Breast Cancer in Older Women: Surgery vs. Hormone Therapy Choices

Understanding Treatment Options for Older Women with Breast Cancer

When older women receive a breast cancer diagnosis, one of the primary considerations is whether surgical intervention is necessary. A significant review published on November 6, 2026, in JAMA Network Open highlights that the decision may rely more on the characteristics of the tumor and the patient's overall health than on their age alone.

Research Overview

A team from UPMC Hillman Cancer Center and Brigham and Women’s Hospital analyzed 29 studies involving 22,821 women aged 65 and older with ER-positive breast cancer, meaning their cancer cells rely on estrogen for growth. The median age among the participants was 83. The research aimed to compare two approaches: starting treatment with surgery or utilizing primary endocrine therapy, which involves hormone-blocking medications.

Survival Rates: A Closer Look

The review examined data from six randomized trials, which included 813 women. The findings indicated that there was no statistically significant difference in overall survival between those who underwent surgery and those who chose hormone therapy. Although surgery slightly edged out in terms of survival rates, the difference was minimal, suggesting it could be attributable to random chance. Additionally, there was no notable discrepancy in breast cancer-specific mortality rates.

Interestingly, a larger percentage of women died from causes unrelated to breast cancer. Among those involved in the trials, 28.8% succumbed to breast cancer, while 47.3% died from other health complications, such as heart disease. This highlights that for many individuals in their 80s, larger health issues may play a more significant role in life expectancy than breast cancer itself.

Cancer Control: The Role of Surgery

Surgery proved effective in managing cancer locally. In a long-term trial, 38% of women undergoing hormone therapy alone experienced cancer progression in the breast after five years, rising to 43% at the ten-year mark. Many of these participants eventually needed surgical intervention as the cancer resurfaced. However, more recent studies focused on carefully selected patients reported extended time before cancer progression, often exceeding four years.

It's important to note that the randomized trials primarily assessed tamoxifen, an established hormone therapy. Many elderly women today are treated with newer options, such as aromatase inhibitors—like Arimidex (anastrozole) or Femara (letrozole)—which function by lowering estrogen levels after menopause. The existing randomized evidence does not directly evaluate these newer therapies as an alternative to surgery.

Identifying Candidates for Non-Surgical Treatment

The study revealed that women with tumors that strongly rely on estrogen, exhibit slow growth (characterized by low grade and low Ki-67 levels), and are smaller, are more likely to benefit from hormone therapy alone. The presence of frailty, other serious health problems, and difficulties with daily activities were linked to less favorable outcomes, mainly due to causes not related to breast cancer.

Given these findings, the authors recommend that healthcare providers consider tumor biology alongside the patient's frailty instead of solely focusing on age when determining candidates for non-surgical hormone therapy. They caution that further research is needed to validate this approach before it becomes a standard practice in clinical settings.

The review did note limitations, including the relatively small size of the randomized trials and the older nature of some of the data, which required estimates from published graphs.

Consultation with Your Oncologist

For those grappling with the choice between surgery and hormone therapy, discussing the following questions with an oncologist can provide clarity:

• How significantly does my tumor rely on estrogen, and how rapidly is it growing according to my pathology report?
• How will my existing health conditions influence the outcome of surgery?
• If I opt for hormone therapy first, how will we monitor its effectiveness, and under what circumstances would I consider surgery again?
• What potential side effects should I prepare for with the recommended hormone therapy?

Ultimately, both treatment paths require commitment and consideration. The optimal choice depends on the specific cancer characteristics, the individual's health, and personal treatment goals.